Emerging Roles of Th9 Cells as an Anti-tumor Helper T Cells

References

• Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991–998. doi:10.1038/ni1102-991.
   PubMed Web of Science ®Google Scholar
• Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov 2019;18:197–218. doi:10.1038/s41573-018-0007-y.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988;319:1676–1680. doi:10.1056/NEJM198812223192527.
   PubMed Web of Science ®Google Scholar
• Antony PA, Piccirillo CA, Akpinarli A, et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005;174:2591–2601. doi:10.4049/jimmunol.174.5.2591.
   PubMed Web of Science ®Google Scholar
• Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 2002;99:16168–16173. doi:10.1073/pnas.242600099.
   PubMed Web of Science ®Google Scholar
• Hung K, Hayashi R, Lafond-Walker A, et al. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998;188:2357–2368. doi:10.1084/jem.188.12.2357.
   PubMed Web of Science ®Google Scholar
• Ramsburg EA, Publicover JM, Coppock D, et al. Requirement for CD4 T cell help in maintenance of memory CD8 T cell responses is epitope dependent. J Immunol 2007;178:6350–6358. doi:10.4049/jimmunol.178.10.6350.
   PubMed Web of Science ®Google Scholar
• Ahrends T, Spanjaard A, Pilzecker B, et al. CD4(+) T cell help confers a cytotoxic T cell effector program including coinhibitory receptor downregulation and increased tissue invasiveness. Immunity 2017;47:848–861. e845. doi:10.1016/j.immuni.2017.10.009.
   PubMed Web of Science ®Google Scholar
• Takeuchi A, Badr MESG, Miyauchi K, et al. CRTAM determines the CD4+ cytotoxic T lymphocyte lineage. J Exp Med 2016;213:123–138. doi:10.1084/jem.20150519.
   PubMed Web of Science ®Google Scholar
• Rollings CM, Sinclair LV, Brady HJM, et al. Interleukin-2 shapes the cytotoxic T cell proteome and immune environment-sensing programs. Sci Signal 2018;11. doi:10.1126/scisignal.aap8112.
   PubMed Web of Science ®Google Scholar
• Huang H, Hao S, Li F, et al. CD4+ Th1 cells promote CD8+ Tc1 cell survival, memory response, tumor localization and therapy by targeted delivery of interleukin 2 via acquired pMHC I complexes. Immunology 2007;120:148–159. doi:10.1111/j.1365-2567.2006.02452.x.
   PubMed Web of Science ®Google Scholar
• Flavell RA, Li B, Dong C, et al. Molecular basis of T-cell differentiation. Cold Spring Harb Symp Quant Biol 1999;64:563–571.
   PubMedGoogle Scholar
• Quezada SA, Simpson TR, Peggs KS, et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010;207:637–650. doi:10.1084/jem.20091918.
   PubMed Web of Science ®Google Scholar
• Li Z, Jiang J, Wang Z, et al. Endogenous interleukin-4 promotes tumor development by increasing tumor cell resistance to apoptosis. Cancer Res 2008;68:8687–8694. doi:10.1158/0008-5472.CAN-08-0449.
   PubMed Web of Science ®Google Scholar
• Korn T, Bettelli E, Oukka M, et al. IL-17 and Th17 Cells. Annu Rev Immunol. 2009;27:485–517. doi:10.1146/annurev.immunol.021908.132710.
   PubMed Web of Science ®Google Scholar
• Awasthi A, Kuchroo VK. Th17 cells: from precursors to players in inflammation and infection. Int Immunol 2009;21:489–498. doi:10.1093/intimm/dxp021.
   PubMed Web of Science ®Google Scholar
• Lee Y, Awasthi A, Yosef N, et al. Induction and molecular signature of pathogenic TH17 cells. Nat Immunol 2012;13:991–999. doi:10.1038/ni.2416.
   PubMed Web of Science ®Google Scholar
• Numasaki M, Fukushi J-I, Ono M, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003;101:2620–2627. doi:10.1182/blood-2002-05-1461.
   PubMed Web of Science ®Google Scholar
• Prabhala RH, Pelluru D, Fulciniti M, et al. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 2010;115:5385–5392. doi:10.1182/blood-2009-10-246660.
   PubMed Web of Science ®Google Scholar
• Kryczek I, Wei S, Zou L, et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 2007;178:6730–6733. doi:10.4049/jimmunol.178.11.6730.
   PubMed Web of Science ®Google Scholar
• Martin-Orozco N, Muranski P, Chung Y, et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009;31:787–798. doi:10.1016/j.immuni.2009.09.014.
   PubMed Web of Science ®Google Scholar
• Muranski P, Boni A, Antony PA, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008;112:362–373. doi:10.1182/blood-2007-11-120998.
   PubMed Web of Science ®Google Scholar
• Malik S, Awasthi A. Transcriptional control of Th9 cells: role of foxo1 in interleukin-9 induction. Front Immunol 2018;9:995.doi:10.3389/fimmu.2018.00995.
   PubMed Web of Science ®Google Scholar
• Schmitt E, Klein M, Bopp T. Th9 cells, new players in adaptive immunity. Trends Immunol 2014;35:61–68. doi:10.1016/j.it.2013.10.004.
   PubMed Web of Science ®Google Scholar
• Uyttenhove C, Simpson RJ, Van Snick J. Functional and structural characterization of P40, a mouse glycoprotein with T-cell growth factor activity. Proc Natl Acad Sci U S A 1988;85:6934–6938. doi:10.1073/pnas.85.18.6934.
   PubMed Web of Science ®Google Scholar
• Renauld JC, Druez C, Kermouni A, et al. Expression cloning of the murine and human interleukin 9 receptor cDNAs. Proc Natl Acad Sci U S A 1992;89:5690–5694. doi:10.1073/pnas.89.12.5690.
   PubMed Web of Science ®Google Scholar
• Arendse B, Van Snick J, Brombacher F. IL-9 is a susceptibility factor in Leishmania major infection by promoting detrimental Th2/type 2 responses. J Immunol 2005;174:2205–2211. doi:10.4049/jimmunol.174.4.2205.
   PubMed Web of Science ®Google Scholar
• Schmitt E, Germann T, Goedert S, et al. IL-9 production of naive CD4+ T cells depends on IL-2, is synergistically enhanced by a combination of TGF-beta and IL-4, and is inhibited by IFN-gamma. J Immunol 1994;153:3989–3996.
   PubMed Web of Science ®Google Scholar
• Veldhoen M, Uyttenhove C, van Snick J, et al. Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol 2008;9:1341–1346. doi:10.1038/ni.1659.
   PubMed Web of Science ®Google Scholar
• Dardalhon V, Awasthi A, Kwon H, et al. IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat Immunol 2008;9:1347–1355. doi:10.1038/ni.1677.
   PubMed Web of Science ®Google Scholar
• Vegran F, Berger H ,Boidot R, et al. The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells. Nat Immunol 2014;15:758–766. doi:10.1038/ni.2925.
   PubMed Web of Science ®Google Scholar
• Xue G, Jin G, Fang J, et al. IL-4 together with IL-1beta induces antitumor Th9 cell differentiation in the absence of TGF-beta signaling. Nat Commun 2019;10:1376. doi:10.1038/s41467-019-09401-9.
   PubMed Web of Science ®Google Scholar
• Chen J, Zhao Y ,Jiang Y, et al. Interleukin-33 contributes to the induction of Th9 cells and antitumor efficacy by dectin-1-activated dendritic cells. Front Immunol 2018;9:1787. doi:10.3389/fimmu.2018.01787.
   PubMed Web of Science ®Google Scholar
• Angkasekwinai P, Chang SH, Thapa M, et al. Regulation of IL-9 expression by IL-25 signaling. Nat Immunol 2010;11:250–256. doi:10.1038/ni.1846.
   PubMed Web of Science ®Google Scholar
• Yao W, Zhang Y, Jabeen R, et al. Interleukin-9 is required for allergic airway inflammation mediated by the cytokine TSLP. Immunity 2013;38:360–372. doi:10.1016/j.immuni.2013.01.007.
   PubMed Web of Science ®Google Scholar
• Malik S, Sadhu S, Elesela S, et al. Transcription factor Foxo1 is essential for IL-9 induction in T helper cells. Nat Commun 2017;8:815. doi:10.1038/s41467-017-00674-6.
   PubMed Web of Science ®Google Scholar
• Murugaiyan G, Beynon V, Pires Da Cunha A, et al. IFN-gamma limits Th9-mediated autoimmune inflammation through dendritic cell modulation of IL-27. J Immunol 2012;189:5277–5283. doi:10.4049/jimmunol.1200808.
   PubMed Web of Science ®Google Scholar
• Xiao X, Balasubramanian S ,Liu W, et al. OX40 signaling favors the induction of T(H)9 cells and airway inflammation. Nat Immunol 2012;13:981–990. doi:10.1038/ni.2390.
   PubMed Web of Science ®Google Scholar
• Niedbala W, Besnard A-G, Nascimento DC, et al. Nitric oxide enhances Th9 cell differentiation and airway inflammation. Nat Commun 2014;5:4575. doi:10.1038/ncomms5575.
   PubMed Web of Science ®Google Scholar
• Elyaman W, Bradshaw EM, Uyttenhove C, et al. IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc Natl Acad Sci U S A 2009;106:12885–12890. doi:10.1073/pnas.0812530106.
   PubMed Web of Science ®Google Scholar
• Beriou G, Bradshaw EM, Lozano E, et al. TGF-beta induces IL-9 production from human Th17 cells. J Immunol 2010;185:46–54. doi:10.4049/jimmunol.1000356.
   PubMed Web of Science ®Google Scholar
• Mohapatra A, Van Dyken SJ, Schneider C, et al. Group 2 innate lymphoid cells utilize the IRF4-IL-9 module to coordinate epithelial cell maintenance of lung homeostasis. Mucosal Immunol 2016;9:275–286. doi:10.1038/mi.2015.59.
   PubMed Web of Science ®Google Scholar
• Wilhelm C, Hirota K, Stieglitz B, et al. An IL-9 fate reporter demonstrates the induction of an innate IL-9 response in lung inflammation. Nat Immunol 2011;12:1071–1077. doi:10.1038/ni.2133.
   PubMed Web of Science ®Google Scholar
• Licona-Limon P, Henao-Mejia J ,Temann AU, et al. Th9 cells drive host immunity against gastrointestinal worm infection. Immunity 2013;39:744–757. doi:10.1016/j.immuni.2013.07.020.
   PubMed Web of Science ®Google Scholar
• Turner J-E, Morrison PJ, Wilhelm C, et al. IL-9-mediated survival of type 2 innate lymphoid cells promotes damage control in helminth-induced lung inflammation. J Exp Med 2013;210:2951–2965. doi:10.1084/jem.20130071.
   PubMed Web of Science ®Google Scholar
• Chen C-Y, Lee J-B, Liu B, et al. Induction of interleukin-9-producing mucosal mast cells promotes susceptibility to IgE-mediated experimental food allergy. Immunity 2015;43:788–802. doi:10.1016/j.immuni.2015.08.020.
   PubMed Web of Science ®Google Scholar
• Stassen M, Müller C, Arnold M, et al. IL-9 and IL-13 production by activated mast cells is strongly enhanced in the presence of lipopolysaccharide: NF-kappa B is decisively involved in the expression of IL-9. J Immunol 2001;166:4391–4398. doi:10.4049/jimmunol.166.7.4391.
   PubMed Web of Science ®Google Scholar
• Chang H-C, Sehra S, Goswami R, et al. The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation. Nat Immunol 2010;11:527–534. doi:10.1038/ni.1867.
   PubMed Web of Science ®Google Scholar
• Gerlach K, Hwang YYi, Nikolaev A, et al. TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells. Nat Immunol 2014;15:676–686. doi:10.1038/ni.2920.
   PubMed Web of Science ®Google Scholar
• Ramming A, Druzd D, Leipe J, et al. Maturation-related histone modifications in the PU.1 promoter regulate Th9-cell development. Blood 2012;119:4665–4674. doi:10.1182/blood-2011-11-392589.
   PubMed Web of Science ®Google Scholar
• Goswami R, Jabeen R, Yagi R, et al. STAT6-dependent regulation of Th9 development. J Immunol 2012;188:968–975. doi:10.4049/jimmunol.1102840.
   PubMed Web of Science ®Google Scholar
• Staudt V, Bothur E, Klein M, et al. Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells. Immunity 2010;33:192–202. doi:10.1016/j.immuni.2010.07.014.
   PubMed Web of Science ®Google Scholar
• Elyaman W, Bassil R, Bradshaw EM, et al. Notch receptors and Smad3 signaling cooperate in the induction of interleukin-9-producing T cells. Immunity 2012;36:623–634. doi:10.1016/j.immuni.2012.01.020.
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Renauld JC, Fibbe WE, et al. IL-2 dependence of IL-9 expression in human T lymphocytes. J Immunol 1992;148:3147–3151.
   PubMed Web of Science ®Google Scholar
• Liao W, Lin JX, Leonard WJ. IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol 2011;23:598–604. doi:10.1016/j.coi.2011.08.003.
   PubMed Web of Science ®Google Scholar
• Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 2010;33:153–165. doi:10.1016/j.immuni.2010.08.004.
   PubMed Web of Science ®Google Scholar
• Olson MR, Verdan FF, Hufford MM, et al. STAT3 Impairs STAT5 Activation in the Development of IL-9-Secreting T Cells. J Immunol 2016;196:3297–3304. doi:10.4049/jimmunol.1501801.
   PubMed Web of Science ®Google Scholar
• Yang XO, Zhang H, Kim B-S, et al. The signaling suppressor CIS controls proallergic T cell development and allergic airway inflammation. Nat Immunol 2013;14:732–740. doi:10.1038/ni.2633.
   PubMed Web of Science ®Google Scholar
• Rivera Vargas T, Humblin E, Vegran F, et al. TH9 cells in anti-tumor immunity. Semin Immunopathol 2017;39:39–46. doi:10.1007/s00281-016-0599-4.
   PubMed Web of Science ®Google Scholar
• Purwar R, Schlapbach C, Xiao S, et al. Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med 2012;18:1248–1253. doi:10.1038/nm.2856.
   PubMed Web of Science ®Google Scholar
• Grimbaldeston MA, Chen C-C, Piliponsky AM, et al. Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo. Am J Pathol 2005;167:835–848. doi:10.1016/S0002-9440(10)62055-X.
   PubMed Web of Science ®Google Scholar
• Abdul-Wahid A, Cydzik M, Prodeus A, et al. Induction of antigen-specific TH 9 immunity accompanied by mast cell activation blocks tumor cell engraftment. Int J Cancer 2016;139:841–853. doi:10.1002/ijc.30121.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Chu X, Chen J, et al. Dectin-1-activated dendritic cells trigger potent antitumour immunity through the induction of Th9 cells. Nat Commun 2016;7:12368. doi:10.1038/ncomms12368.
   PubMed Web of Science ®Google Scholar
• Park J, Li H, Zhang M, et al. Murine Th9 cells promote the survival of myeloid dendritic cells in cancer immunotherapy. Cancer Immunol Immunother 2014;63:835–845. doi:10.1007/s00262-014-1557-4.
   PubMed Web of Science ®Google Scholar
• Schaer DA, Murphy JT, Wolchok JD. Modulation of GITR for cancer immunotherapy. Curr Opin Immunol 2012;24:217–224. doi:10.1016/j.coi.2011.12.011.
   PubMed Web of Science ®Google Scholar
• Kim I-K, Kim B-S, Koh C-H, et al. Glucocorticoid-induced tumor necrosis factor receptor-related protein co-stimulation facilitates tumor regression by inducing IL-9-producing helper T cells. Nat Med 2015;21:1010–1017. doi:10.1038/nm.3922.
   PubMed Web of Science ®Google Scholar
• Xiao X, Shi X, Fan Y, et al. GITR subverts Foxp3(+) Tregs to boost Th9 immunity through regulation of histone acetylation. Nat Commun 2015;6:8266. doi:10.1038/ncomms9266.
   PubMed Web of Science ®Google Scholar
• Lu Y, Wang Q, Xue G, et al. Th9 cells represent a unique subset of CD4(+) T cells endowed with the ability to eradicate advanced tumors. Cancer Cell 2018;33:1048–1060 e1047, doi:10.1016/j.ccell.2018.05.004.
   PubMed Web of Science ®Google Scholar